Hydrophilic interaction liquid chromatography (HILIC) has emerged as a critical separation technique for pharmaceutical scientists confronted with the analytical challenges posed by highly polar and hydrophilic compounds. Unlike reversed-phase liquid chromatography (RP-LC), where polar molecules elute near the void volume with poor retention, HILIC exploits the differential partitioning of analytes between a water-enriched layer immobilized on a polar stationary phase and a mobile phase rich in organic solvent, typically acetonitrile. This mode of chromatography has become indispensable for the analysis of polar drug substances, metabolites, amino acids, carbohydrates, nucleotides, and other hydrophilic pharmaceutical compounds that defy adequate retention and resolution on conventional C18 or C8 columns. BOC Sciences' HILIC services provide the specialized analytical infrastructure required to address these challenging separations across drug discovery and development workflows.
Partitioning: Partitioning is generally the dominant retention mechanism in HILIC. Under organic-rich mobile phase conditions, a water-enriched layer forms on the surface of the polar stationary phase and acts as a pseudo-stationary phase. Polar analytes preferentially move from the acetonitrile-rich mobile phase into this aqueous layer according to their hydrophilicity and affinity for the water-rich environment. As a result, compounds with stronger polarity or greater hydrogen-bonding capacity usually show longer retention, while relatively hydrophobic compounds elute earlier. This mechanism explains the characteristic HILIC elution behavior in which highly polar analytes are retained more strongly than less polar species.
Hydrogen Bonding: Hydrogen bonding provides an important secondary contribution to HILIC retention, especially for analytes containing multiple hydrogen bond donor or acceptor groups. Stationary phases modified with hydroxyl, amide, amino, or other polar functional groups can form hydrogen-bonding interactions with analytes such as carbohydrates, glycosides, nucleosides, peptides, and other highly functionalized molecules. These interactions can enhance retention beyond simple partitioning and often play a major role in improving selectivity between structurally similar compounds. For analytes with abundant hydroxyl or amide groups, hydrogen bonding may significantly influence both retention strength and elution order.
Electrostatic Interactions: Electrostatic interactions become particularly important when either the analyte or the stationary phase carries an ionic charge. Charged stationary phases can introduce anion-exchange or cation-exchange behavior, providing additional selectivity for oppositely charged analytes such as organic acids, bases, nucleotides, phosphorylated compounds, and other ionizable pharmaceutical molecules. Even on nominally neutral or bare silica phases, residual silanol groups may interact with basic analytes and contribute to retention or peak tailing. Because electrostatic effects are highly sensitive to mobile phase pH, buffer type, and salt concentration, careful control of these parameters is essential for achieving reproducible HILIC retention and reliable peak shape.
Stationary phase selection has a direct influence on retention strength, selectivity, peak shape, and reproducibility in HILIC. Bare silica, neutral polar, charged, and zwitterionic phases each provide different balances of partitioning, hydrogen bonding, and electrostatic interaction. Because pharmaceutical compounds often contain multiple polar or ionizable groups, choosing the appropriate phase chemistry is a key step in HILIC method development.
Bare silica columns are often used as a broad starting point because of their strong hydrophilic retention and high solvent compatibility, while neutral phases provide more predictable hydrogen bonding and partitioning behavior. Charged and zwitterionic phases are especially useful when additional selectivity is needed for ionizable compounds, amino acids, nucleosides, organic acids, or other highly polar analytes.
Table.1 Common HILIC Stationary Phase Types and Application Considerations.
| Stationary Phase Type | Typical Chemistry | Main Retention Features | Suitable Applications | Key Considerations |
| Bare silica | Unbonded silica surface with silanol groups. | Strong hydrophilic retention through partitioning, hydrogen bonding, and possible silanol-based electrostatic interactions. | Carbohydrates, glycans, highly polar drug substances, small polar impurities. | May cause peak tailing for basic analytes if silanol interactions are not controlled. |
| Neutral polar phase | Amide, diol, polyol, or other non-ionizable polar bonded groups. | Retention mainly driven by partitioning and hydrogen bonding with reduced electrostatic contribution. | Glycans, carbohydrates, neutral polar compounds, polar metabolites. | Often provides improved peak shape for charged analytes compared with bare silica. |
| Charged phase | Amino, sulfonic acid, quaternary ammonium, or other ion-exchange functional groups. | Combines HILIC retention with anion-exchange or cation-exchange selectivity. | Organic acids, nucleotides, phosphorylated metabolites, basic compounds, acidic impurities. | Retention is strongly affected by mobile phase pH and buffer concentration. |
| Zwitterionic phase | Functional groups containing both positive and negative charges, such as sulfoalkylbetaine groups. | Strong hydrophilic retention with balanced surface charge and reproducible selectivity. | Amino acids, nucleosides, water-soluble vitamins, polar ionizable compounds. | Provides broad applicability and good peak shapes for both acidic and basic analytes. |
Mobile phase optimization in HILIC requires careful adjustment of organic solvent content, water percentage, buffer type, buffer concentration, pH, and additives. Unlike reversed-phase chromatography, HILIC retention generally increases as the percentage of organic solvent increases, because a higher organic content strengthens the partitioning of polar analytes into the water-enriched layer on the stationary phase surface.
Acetonitrile is the most commonly used organic modifier because it supports strong HILIC retention and is compatible with MS-based detection. Buffer selection and pH control are equally important for ionizable pharmaceutical compounds, as they influence analyte charge state, stationary phase surface behavior, electrostatic interactions, peak shape, and retention reproducibility.
Table.2 Key HILIC Mobile Phase Parameters and Their Influence on Retention.
| Mobile Phase Parameter | Typical Range | Impact on Retention and Selectivity | Practical Optimization Notes |
| Acetonitrile content | 60% to 95% | Higher acetonitrile increases retention of polar analytes by strengthening partitioning into the water-enriched stationary phase layer. | Often optimized first because it has the strongest effect on retention time and elution order. |
| Water content | 5% to 40% | Higher water content generally decreases HILIC retention by weakening analyte partitioning into the surface water layer. | Very low water content may reduce reproducibility or analyte solubility for some compounds. |
| Buffer concentration | 5 mM to 50 mM | Higher buffer concentration suppresses excessive electrostatic interactions and promotes more reproducible retention. | Useful for improving peak shape of ionizable analytes, but excessive salt may affect MS response. |
| Mobile phase pH | 3.0 to 7.0 for many silica-based columns | Affects analyte ionization state and stationary phase surface charge, influencing hydrophilicity and electrostatic interactions. | Should be selected based on analyte pKa, column stability, and desired retention behavior. |
| Buffer type | Ammonium acetate, ammonium formate | Volatile buffers provide MS compatibility while controlling ionic strength and pH for consistent peak shape. | Commonly selected for LC-MS-compatible HILIC methods. |
| Additives | 0.01% to 0.1% formic acid or other suitable additives | May improve peak shape, enhance ionization efficiency, or suppress undesirable interactions for ionizable analytes. | Should be evaluated carefully because additives can change retention, selectivity, and detector response. |
Many pharmaceutical compounds are intentionally designed with polar or ionizable groups to improve solubility, binding interactions, or transport behavior. These properties may be beneficial for drug research but challenging for chromatographic analysis. Polar molecules may show low retention on reversed-phase columns, poor separation from early-eluting matrix components, or weak UV response that requires MS detection. HILIC provides an orthogonal approach for separating compounds that are too hydrophilic for conventional reversed-phase methods and can be particularly useful when paired with UHPLC testing for higher resolution and shorter run times.
Aminoglycosides and many highly polar antibiotic compounds contain multiple amino and hydroxyl groups, giving them strong hydrophilicity and limited retention in reversed-phase LC without ion-pairing reagents or derivatization. HILIC can provide direct retention of these molecules under organic-rich conditions, reducing the need for nonvolatile ion-pairing additives that may interfere with MS detection. Because aminoglycoside-like structures are often highly basic and capable of multiple ionic interactions, stationary phase screening is essential. Bare silica may provide strong retention, while zwitterionic or neutral polar phases may improve peak symmetry and reduce excessive adsorption.
For this compound class, method development usually focuses on controlling peak tailing, carryover, and response reproducibility. Buffer concentration, pH, sample solvent composition, and injection volume all influence performance. When MS detection is used, careful source tuning and transition selection can help distinguish structurally related compounds. A robust HILIC method for aminoglycoside and polar antibiotic analysis should provide enough retention to separate the target molecule from excipient-derived or matrix-derived interferences while maintaining sensitivity and consistent recovery across repeated injections.
Water-soluble vitamins and polar nutraceutical molecules often contain multiple hydroxyl groups, amide groups, phosphate groups, or ionic functionalities. These features make them suitable candidates for HILIC analysis, especially when several compounds with different polarity and charge states must be monitored in a single method. Vitamin B-group molecules, phosphorylated derivatives, and other hydrophilic nutraceutical components may elute poorly in reversed-phase LC but show useful selectivity under HILIC conditions.
Analytical scientists developing HILIC methods for these molecules often need to balance retention with compound stability. Some polar vitamins and related molecules may be sensitive to light, oxidation, pH, or temperature during sample preparation. Mobile phase selection should therefore support both chromatographic performance and analyte stability. When multiple analytes are included, gradient design may be required to elute strongly retained species without compromising early peak resolution. HILIC-MS can also be useful when UV absorbance is weak or when co-eluting components are difficult to distinguish by optical detection.
Polar basic drug substances are common in pharmaceutical research because amine-containing groups can improve solubility and influence molecular recognition. However, these same groups may cause chromatographic challenges, including low reversed-phase retention, silanol interaction, peak tailing, and retention variability. HILIC offers an alternative retention mode that can improve separation of basic analytes, but method conditions must be designed to control ionic interactions. Acidic mobile phase additives may enhance protonation and ESI response, while buffer concentration can reduce uncontrolled adsorption and improve peak shape.
For polar basic drugs, a practical HILIC development strategy begins with understanding pKa, logD, hydrogen-bonding capacity, and structural features that may interact with stationary phase sites. Neutral amide or diol-type phases may be suitable when peak shape is the primary concern, while charged or zwitterionic phases may provide improved selectivity for closely related analogs. The final method should demonstrate stable retention time, symmetrical peaks, and reliable quantitation across the concentration range required for the research objective.
Nucleoside and nucleotide analog drug compounds often contain heterocyclic bases, ribose-like groups, phosphate groups, and multiple hydrogen-bonding sites. These structures are highly compatible with HILIC separation because they can participate in partitioning, hydrogen bonding, and ionic interactions. HILIC is particularly valuable when separating parent analogs from phosphorylated derivatives, hydrolysis products, synthetic impurities, or closely related metabolites. The technique can also help resolve compounds that share similar hydrophobicity but differ in polarity, charge distribution, or phosphate content.
Nucleotide analog analysis can be challenging because phosphate-containing species may interact strongly with metal surfaces, charged stationary phases, or residual active sites. Mobile phase additives, column hardware selection, sample solvent composition, and wash conditions may all influence recovery and carryover. HILIC-MS or HILIC-HRMS workflows are often preferred when structural confirmation or accurate mass information is needed for unknown polar components. For research programs involving nucleoside analogs, BOC Sciences can combine HILIC separation with MS-based detection to support targeted quantification and unknown peak investigation.
Table.3 Representative Polar Drug Molecule Classes Suitable for HILIC Analysis.
| Compound Class | Common Analytical Challenge | How HILIC Helps |
| Aminoglycoside-Like Compounds | Very high polarity, multiple basic sites, poor reversed-phase retention. | Provides direct retention under organic-rich conditions and supports MS-compatible workflows. |
| Water-Soluble Vitamins | Strong hydrophilicity, diverse charge states, weak or overlapping UV response. | Improves retention and enables multi-analyte separation with MS detection if needed. |
| Polar Basic Drugs | Peak tailing, early elution, ionic interaction with active sites. | Offers orthogonal selectivity and tunable electrostatic control through pH and buffer selection. |
| Nucleoside and Nucleotide Analogs | Multiple hydrogen-bonding sites, phosphate-related adsorption, related impurity complexity. | Enhances separation of parent compounds, phosphorylated forms, and hydrophilic related substances. |
Our HILIC analysis supports the retention, separation, identification, and quantitative determination of highly polar, hydrophilic, and ionizable drug molecules in complex pharmaceutical research samples.
Drug metabolism introduces polar functional groups into drug molecules through enzymatic transformations, producing metabolites that are frequently more hydrophilic than the parent compound and increasingly difficult to retain and resolve by reversed-phase chromatography. Phase I metabolic reactions introduce or expose polar functional groups through oxidation, reduction, and hydrolysis, while Phase II conjugation reactions attach highly polar endogenous moieties such as glucuronic acid, sulfate, or glutathione to the drug or its Phase I metabolites. HILIC, particularly when coupled with mass spectrometry, provides a powerful analytical approach for metabolite identification, quantitative analysis, and metabolomics investigations in pharmaceutical research.
Hydroxylated Phase I Metabolites: Hydroxylation is one of the most common Phase I metabolic transformations and introduces one or more hydroxyl groups into the parent drug structure. This structural change substantially increases analyte polarity and may shift the metabolite outside the practical retention range of reversed-phase columns, especially when the parent compound is already moderately polar. HILIC-MS is well suited for these metabolites because hydroxylated structures can be retained through partitioning into the water-enriched stationary phase layer and hydrogen bonding with polar stationary phase groups. Hydroxylated metabolites of nonsteroidal anti-inflammatory compounds, antidepressant-related molecules, and antiepileptic compound classes often show enhanced retention on bare silica, amide, and zwitterionic HILIC columns. Metabolite analysis and identification workflows commonly use HILIC-MS as a complementary strategy to RP-LC for broader coverage of polar metabolic profiles.
N-Oxidation and S-Oxidation Products: N-oxidation and S-oxidation products are formed when oxygen is transferred to nitrogen- or sulfur-containing functional groups, generating N-oxide or sulfoxide metabolites with increased polarity and stronger hydrogen-bonding potential. These metabolites often display basic, amphoteric, or strongly polar characteristics that support effective retention on zwitterionic and bare silica HILIC phases. Compared with the corresponding parent compounds, N-oxide and sulfoxide metabolites typically exhibit stronger interaction with the aqueous stationary phase layer and improved separation from less polar matrix components. When combined with accurate mass measurement and MS/MS fragmentation, HILIC-MS can help distinguish oxidation products from closely related metabolites with similar molecular weights but different chromatographic behavior.
Dealkylation-Related Polar Metabolites: Dealkylation reactions remove alkyl groups and expose more polar functional groups such as hydroxyl, phenolic, or primary amine moieties. This transformation often increases hydrophilicity while decreasing hydrophobic interaction strength, making the resulting metabolites less suitable for conventional reversed-phase retention. HILIC provides orthogonal selectivity by retaining these exposed polar groups through partitioning, hydrogen bonding, and, when ionizable groups are present, electrostatic interactions. This capability is especially useful when metabolite reference standards are unavailable and structural assignments depend on the combined interpretation of retention behavior, exact mass, isotope pattern, and fragmentation data.
Glucuronide Metabolites: Glucuronidation attaches glucuronic acid to drug molecules or Phase I metabolites through O-, N-, S-, or C-linkages, producing conjugates with markedly increased hydrophilicity. Because glucuronides contain multiple hydroxyl groups and a carboxylic acid moiety, they are often poorly retained by reversed-phase columns without specialized conditions. HILIC, particularly with amino, amide, or zwitterionic phases, provides effective retention through partitioning into the water-enriched surface layer and multiple hydrogen-bonding interactions with the sugar moiety. This makes HILIC-MS a practical option for resolving glucuronide conjugates from parent compounds, Phase I metabolites, and other polar components in complex research samples.
Sulfate and Amino Acid Conjugates: Sulfate conjugates contain a strongly acidic sulfate ester group that confers high polarity and pronounced ionic character. These properties make them highly suitable for HILIC separation, especially on amino, bare silica, or zwitterionic phases where partitioning and electrostatic interactions can both contribute to retention. Other Phase II metabolites, including glutathione conjugates, mercapturic acids, and amino acid conjugates, also benefit from HILIC retention mechanisms because their peptide, amino acid, or sulfur-containing moieties provide multiple polar interaction sites. In HILIC-MS workflows, volatile ammonium acetate or ammonium formate buffers are commonly used to support retention reproducibility while maintaining compatibility with mass spectrometric detection.
Acyl Glucuronides: Acyl glucuronides are formed from carboxylic acid-containing drug molecules and can be analytically challenging because they may undergo rearrangement or hydrolysis under unsuitable sample handling or mobile phase conditions. HILIC methods for acyl glucuronides therefore require careful control of pH, buffer composition, sample temperature, and analysis time to preserve the native conjugate profile as much as possible. Mild acidic conditions are often preferred to reduce unwanted transformation while maintaining adequate retention on amide or zwitterionic HILIC columns. Direct HILIC-MS/MS analysis of these labile conjugates can provide more representative information about the metabolite profile than workflows that convert conjugates back to the parent compound before analysis.
Expanded Coverage of Polar Endogenous Metabolites: Untargeted metabolomics aims to capture a broad range of small molecules in biological or biochemical systems, many of which are highly polar and poorly retained by reversed-phase chromatography. HILIC-MS is particularly valuable for endogenous metabolites such as amino acids, organic acids, nucleotides, sugars, coenzymes, and redox-related molecules. By retaining these hydrophilic compounds before high-resolution mass spectrometric detection, HILIC significantly expands metabolome coverage and enables simultaneous observation of hundreds to thousands of polar features in a single analytical workflow. This broader coverage is essential for studying compound-related changes in energy metabolism, nucleotide synthesis, amino acid utilization, and oxidative balance.
Drug-Induced Pathway Profiling: HILIC-HRMS can be used to compare metabolite abundance patterns between compound-treated and reference samples, helping researchers identify pathway-level changes associated with drug exposure. Changes in glycolysis, tricarboxylic acid cycle intermediates, nucleotide metabolism, amino acid turnover, carnitine-related pathways, and redox metabolism are often reflected by polar metabolites that are well retained under HILIC conditions. Because these compounds may elute too early or with poor peak shape in reversed-phase methods, HILIC provides an essential complementary separation mode for pathway-focused metabolomics studies. The resulting data can support mechanistic interpretation of compound effects and help prioritize metabolic pathways for deeper investigation.
Research Biomarker Discovery and Mechanistic Interpretation: HILIC-based metabolomics supports the discovery of research-use metabolic markers by improving the detection of polar metabolites that reflect biochemical pathway activity. When combined with accurate mass measurement, isotope pattern analysis, MS/MS fragmentation, and database-assisted annotation, HILIC-MS can help distinguish structurally related metabolites and improve confidence in pathway mapping. This approach is especially useful in pharmaceutical research programs that require a systems-level understanding of compound-induced metabolic changes, comparison of candidate molecules, or exploration of metabolic response patterns across different experimental models.
Table.4 Drug Metabolite Classes and HILIC Analytical Approaches.
| Metabolite Class | Key Structural Features | Preferred HILIC Phase | Mobile Phase Considerations |
| Hydroxylated Phase I metabolites | Added hydroxyl groups; increased H-bonding capacity | Bare silica, zwitterionic | 80-90% acetonitrile, ammonium acetate 10-20 mM, pH 3.0-5.0 |
| N-oxides and sulfoxides | Polar oxygenated nitrogen or sulfur | Zwitterionic, amide | 75-85% acetonitrile, ammonium formate 10 mM, pH 3.0-4.0 |
| O-glucuronides | Sugar carboxylic acid moiety; multiple hydroxyl groups | Amino, zwitterionic | 70-80% acetonitrile, ammonium acetate 20 mM, pH 4.0-6.0 |
| N-glucuronides | Nitrogen-linked glucuronic acid; amphoteric character | Zwitterionic, bare silica | 75-85% acetonitrile, ammonium acetate 10-20 mM, pH 3.5-5.0 |
| Sulfate conjugates | Strongly acidic sulfate ester; high polarity | Amino, bare silica | 70-80% acetonitrile, ammonium acetate 20-50 mM, pH 4.0-6.0 |
| Acyl glucuronides | Reactive ester-linked glucuronic acid; labile | Amide, zwitterionic | 75-85% acetonitrile, ammonium formate 10 mM, pH 3.0-4.0 |
| Glutathione conjugates | Tripeptide moiety; multiple ionizable groups | Zwitterionic, bare silica | 70-80% acetonitrile, ammonium acetate 20 mM, pH 3.0-4.5 |
BOC Sciences offers HILIC, HILIC-MS, and HILIC-MS/MS analytical capabilities to support the separation, identification, and quantitative determination of diverse polar drug metabolites in complex research samples.
Despite its analytical advantages, HILIC presents distinct challenges that pharmaceutical analysts must understand and systematically address to achieve reliable and reproducible results. The high organic mobile phase content, the water-enriched stationary phase layer, and the multiple retention mechanisms operating simultaneously create a separation environment that is more complex and sometimes less predictable than reversed-phase chromatography. Common issues include poor retention of certain analyte classes, peak shape problems, retention time instability, matrix effects in MS detection, carryover, and sensitivity limitations.
While HILIC is designed to retain polar compounds, certain highly polar or multiply charged analytes may still exhibit insufficient retention even at high acetonitrile concentrations. Small, highly polar molecules such as glycine, creatinine, and urea, as well as small organic acids like formic acid and acetic acid, may elute close to the column void volume due to their weak partitioning into the water-enriched layer relative to their affinity for the bulk organic mobile phase. To address poor retention, analysts should first evaluate alternative stationary phases with stronger hydrophilic character, such as bare silica or amino phases, which provide additional hydrogen bonding or electrostatic interactions beyond simple partitioning. Increasing the buffer concentration can enhance retention for charged analytes by modifying the ionic strength of the water-enriched layer, while adjusting mobile phase pH to maximize the degree of ionization can strengthen electrostatic contributions.
For analytes that remain poorly retained after stationary phase and mobile phase optimization, derivatization strategies can be employed to introduce additional hydrophilic or ionizable groups. Alternatively, analysts may consider specialized HILIC phases such as those with mixed-mode characteristics that combine hydrophilic partitioning with ion exchange or reversed-phase interactions. When retention cannot be sufficiently improved, sample preparation approaches such as evaporation and reconstitution in a high-organic solvent compatible with HILIC injection requirements may enable adequate sensitivity despite limited retention.
Peak shape issues in HILIC frequently arise from mismatches between the sample solvent and the mobile phase, excessive injection volumes, or secondary interactions between analytes and the stationary phase. When samples are dissolved in aqueous solvents and injected onto a HILIC column equilibrated with high-organic mobile phase, the injected water disrupts the water-enriched stationary phase layer at the column head, causing temporary local changes in retention that manifest as peak broadening, splitting, or fronting. This problem is minimized by dissolving samples in a solvent composition close to the initial mobile phase conditions (typically 90-95% acetonitrile with appropriate buffer) or by limiting injection volume to less than 2-5 microliters for analytical scale columns.
Peak tailing in HILIC often indicates secondary interactions, particularly electrostatic attraction between basic analytes and negatively charged silanol groups on silica-based columns. This issue is addressed by increasing buffer concentration to shield electrostatic interactions, by adjusting pH to suppress either analyte ionization or silanol ionization, or by switching to a zwitterionic or polymer-based stationary phase with reduced surface charge. Additives such as trifluoroacetic acid or formic acid at low concentrations can improve peak shapes for basic compounds by competing for interaction sites and enhancing ion pairing in the mobile phase.
Retention time stability is a well-known challenge in HILIC due to the sensitivity of the water-enriched stationary phase layer to changes in mobile phase composition. Unlike reversed-phase chromatography, where column equilibration is relatively rapid, HILIC columns require extended equilibration times when mobile phase conditions are changed because the water content at the stationary phase surface must reach a new equilibrium with the bulk mobile phase. When gradient elution is employed, incomplete re-equilibration between injections can cause retention time drift, with earlier-eluting peaks showing greater variability than later-eluting compounds. Analysts should allow at least 10-20 column volumes of equilibration at initial gradient conditions between injections, with longer equilibration times recommended when method development has identified a particularly sensitive operating point.
Temperature fluctuations also impact HILIC retention time stability because the water distribution between the mobile and stationary phases is temperature-dependent. Maintaining the column in a thermostatted compartment set at a constant temperature, typically 25-40°C, minimizes this source of variability. When retention time drift persists despite adequate equilibration and temperature control, the column may be experiencing phase collapse or chemical degradation, particularly if mobile phase pH has exceeded the manufacturer's recommended range. Regular monitoring of retention time precision across sequences and replacement of columns showing progressive deterioration ensures data reliability in routine HILIC applications.
Matrix effects, defined as the suppression or enhancement of analyte ionization in the mass spectrometer source due to co-eluting matrix components, represent a significant challenge in HILIC-MS bioanalysis. The high organic content of HILIC mobile phases promotes efficient electrospray ionization, but biological matrices such as plasma, urine, and tissue extracts contain endogenous compounds including phospholipids, salts, and metabolites that can co-elute with the analyte and alter ionization efficiency. Matrix effects in HILIC may differ substantially from those observed in RP-LC because the co-elution profile is different, with highly polar endogenous compounds retained and eluted in HILIC while hydrophobic matrix components such as triglycerides and phospholipids elute in the void.
Systematic evaluation of matrix effects through post-extraction spike experiments is essential during HILIC-MS method development. When significant matrix effects are identified, mitigation strategies include improved sample preparation (protein precipitation with acetonitrile, solid-phase extraction with selective sorbents, or liquid-liquid extraction), chromatographic optimization to shift the analyte away from interfering matrix peaks, or the use of stable isotope-labeled internal standards that compensate for ionization variability. Dilution of the extracted sample reduces the absolute amount of matrix introduced per injection, often sufficient to bring matrix effects within acceptable limits while maintaining adequate sensitivity for the target analytes.
Carryover, the appearance of analyte signal in blank injections following high-concentration samples, is particularly problematic in HILIC analysis of strongly polar compounds that may adsorb to multiple surfaces in the chromatographic system. The same hydrogen bonding and electrostatic interactions that provide retention on the column can cause analytes to adsorb to injector needles, valve rotors, and tubing surfaces, releasing in subsequent blank injections. Minimizing carryover requires careful selection of wetted materials, with polyether ether ketone (PEEK) and certain ceramic materials preferred over stainless steel for highly polar analytes prone to metal coordination.
Methodological approaches to reduce carryover include incorporating a strong wash solvent in the autosampler programming, using wash solvents that effectively disrupt hydrogen bonding (such as water or water-acetonitrile mixtures with elevated buffer concentration), and implementing needle wash cycles between injections. When carryover persists despite these measures, the use of an internal standard with similar adsorption characteristics allows correction of quantification bias. For trace-level quantification where carryover cannot be entirely eliminated, blank injections should be strategically placed within the analytical sequence to monitor and account for residual carryover effects.
While HILIC generally provides enhanced ESI-MS sensitivity due to the high organic mobile phase content, certain situations can lead to unexpectedly low sensitivity. Poor chromatographic focusing at the column inlet due to sample solvent incompatibility can cause peak dispersion and reduced peak height, directly impacting sensitivity. Ensuring that the sample solvent composition closely matches or is slightly stronger than the initial mobile phase conditions promotes efficient on-column focusing. Ionization suppression from inadequate mobile phase additive selection can also limit sensitivity; volatile acids such as formic acid and acetic acid typically enhance positive-mode ionization, while ammonium additives can improve ionization efficiency for certain compound classes through adduct formation.
Poor reproducibility in HILIC often traces to inconsistent sample preparation, inadequate column equilibration, or variable water quality in mobile phase preparation. The water content of HILIC mobile phases must be carefully controlled because small variations in the organic-water ratio translate into significant retention changes. Using high-purity water (Type I, 18.2 MΩ·cm) and HPLC-grade acetonitrile, preparing mobile phases gravimetrically rather than volumetrically for critical applications, and controlling laboratory temperature and humidity during mobile phase preparation all contribute to improved method reproducibility. Regular system suitability checks with reference standards at the beginning and end of analytical sequences provide early warning of performance drift.
Table.5 Common Challenges in HILIC Analysis and Practical Troubleshooting Strategies.
| Common Challenge | Possible Causes | Optimization Strategies |
| Poor retention of highly polar or charged analytes | Weak partitioning, unsuitable column chemistry, or insufficient ionic interaction. | Change stationary phase, increase acetonitrile, adjust pH, or optimize buffer strength. |
| Peak tailing, broadening, or unstable peak shape | Sample solvent mismatch, large injection volume, or secondary surface interactions. | Use high-organic sample solvent, reduce injection volume, adjust pH, or switch column phase. |
| Retention time drift and insufficient equilibration | Incomplete column equilibration, mobile phase variation, temperature fluctuation, or column aging. | Extend equilibration, control temperature, prepare mobile phases consistently, and monitor column performance. |
| Matrix effects in HILIC-MS and HILIC-MS/MS analysis | Co-eluting salts, endogenous metabolites, phospholipids, or other matrix components. | Improve sample cleanup, optimize separation, dilute extracts, or use suitable internal standards. |
| Carryover and adsorption of strongly polar compounds | Adsorption to injector, tubing, valve, needle, or metal surfaces. | Optimize wash solvent, add needle wash cycles, evaluate system materials, and include blank injections. |
| Low sensitivity and poor reproducibility | Poor focusing, ionization suppression, inconsistent mobile phase preparation, or inadequate equilibration. | Match sample solvent, optimize additives, use high-purity solvents, and run system suitability checks. |
BOC Sciences offers comprehensive HILIC-based analytical services designed to address the full spectrum of polar compound characterization challenges across pharmaceutical research and development. Our integrated analytical platforms combine state-of-the-art HILIC separation technology with advanced mass spectrometric detection to deliver reliable data for drug substance analysis, metabolite profiling, impurity identification, and metabolomics investigations. The following service offerings represent our core capabilities in hydrophilic interaction chromatography, supported by experienced analytical scientists and robust quality systems.
Developing a robust HILIC method requires systematic evaluation of stationary phase chemistry, mobile phase composition, and instrumental parameters to achieve adequate retention, selectivity, and sensitivity for the target analytes. BOC Sciences provides customized HILIC method development services that address the unique challenges of polar pharmaceutical compounds, from early-stage candidate selection through late-stage development and quality control. Our method development process begins with a thorough understanding of analyte properties, including pKa, logP, and structural features, which guide the selection of initial column and mobile phase conditions from a diverse inventory of bare silica, amide, zwitterionic, amino, and diol stationary phases.
Method optimization employs design-of-experiments approaches to efficiently identify optimal conditions for acetonitrile content, buffer concentration, pH, and additive selection, ensuring that the final method delivers the required performance characteristics. Following development, methods are validated in accordance with industry-accepted guidelines to demonstrate specificity, linearity, accuracy, precision, detection limit, quantitation limit, robustness, and solution stability. BOC Sciences' HILIC method development and validation capabilities support potency assays, purity determination, impurity profiling, and dissolution testing for polar drug substances that cannot be adequately analyzed by conventional RP-HPLC methods.
Understanding the metabolic fate of drug candidates is essential for predicting pharmacokinetic behavior, identifying potential drug-drug interactions, and assessing safety risks associated with reactive metabolite formation. BOC Sciences offers HILIC-MS metabolite profiling services that complement traditional RP-LC approaches, ensuring comprehensive coverage of polar and hydrophilic metabolites that might otherwise be missed. Our metabolite identification workflows integrate HILIC separation with high-resolution accurate mass spectrometry and MS/MS fragmentation analysis to elucidate the structures of Phase I and Phase II metabolites, including hydroxylated products, glucuronides, sulfates, glutathione conjugates, and other polar biotransformation products.
For metabolomics applications, BOC Sciences provides untargeted profiling services using HILIC-HRMS platforms that capture a broad spectrum of endogenous polar metabolites, including amino acids, organic acids, nucleotides, carbohydrates, and cofactors. Drug-induced metabolic pathway perturbations are identified through multivariate statistical analysis of metabolomics datasets, providing mechanistic insights into drug pharmacology and supporting biomarker discovery efforts. Both targeted and untargeted HILIC-MS metabolomics services are available for in vitro cell-based studies, in vivo animal models, and clinical sample analysis, with experienced bioinformaticians available for data interpretation and pathway analysis.
Impurity profiling of pharmaceutical drug substances and drug products requires analytical methods capable of detecting, identifying, and quantifying all significant impurities, including polar byproducts, degradants, and residual process-related compounds. HILIC provides orthogonal selectivity to RP-HPLC for impurity profiling, often revealing polar impurities that co-elute with the drug substance or are unretained in reversed-phase systems. BOC Sciences employs HILIC-based impurity profiling as part of a comprehensive analytical strategy that combines multiple chromatographic and detection techniques to ensure complete impurity coverage.
When unknown peaks are detected during HILIC impurity profiling, our scientists employ a systematic identification workflow that combines retention time analysis, accurate mass determination by HRMS, MS/MS fragmentation pattern interpretation, and comparison with authentic reference materials when available. For structurally novel impurities not represented in spectral libraries, structure characterization is supported by preparative HILIC isolation followed by nuclear magnetic resonance (NMR) spectroscopic analysis for definitive structure elucidation. Impurities identification and characterization services at BOC Sciences provide the structural certainty required for toxicological qualification, process optimization, and regulatory documentation of polar drug substance impurities.
Table.6 BOC Sciences HILIC Analytical Services for Polar Drug Molecules and Metabolites.
| Service Name | Description | Inquiry |
| HILIC Services | Comprehensive hydrophilic interaction liquid chromatography for separation and analysis of polar drug molecules, metabolites, and hydrophilic pharmaceutical compounds. | Inquiry |
| Chromatography Testing | Broad-spectrum chromatographic analysis including HILIC, HPLC, UHPLC, and ion chromatography for pharmaceutical quality control and method development applications. | Inquiry |
| LC-MS Testing | Liquid chromatography-mass spectrometry platforms combining HILIC and RP-LC separation with MS detection for polar compound identification and quantification. | Inquiry |
| Metabolite Analysis and Identification | HILIC-MS metabolite profiling, structural elucidation, and quantitative analysis of drug metabolites in biological matrices across discovery and development stages. | Inquiry |
| Impurity Isolation and Identification | Preparative isolation of polar impurities using HILIC followed by definitive structural identification through mass spectrometry and NMR spectroscopy. | Inquiry |
| Method Development | Custom HILIC method development and optimization for polar pharmaceutical analytes, including column selection, mobile phase design, and validation support. | Inquiry |
| Structure Characterization | Multi-technique structural elucidation of unknown polar impurities and metabolites using HILIC-HRMS, MS/MS fragmentation analysis, and complementary spectroscopic methods. | Inquiry |
Our analytical scientists specialize in HILIC method development and polar compound characterization for pharmaceutical applications. Contact us to discuss your specific project requirements and learn how our integrated HILIC-MS platforms can accelerate your drug development program.
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
